Kedrion S.p.A. and ProMetic Life Sciences Inc. Form Strategic Alliance to Develop Orphan Drugs from Plasma

Published: Mar 13, 2007

LUCCA, ITALY, ANNAPOLIS, MD and MONTREAL -- (MARKET WIRE) -- March 13, 2007 -- Kedrion S.p.A. and ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") have formed a strategic alliance to develop orphan drugs derived from human plasma utilizing ProMetic's proprietary manufacturing process, the Plasma Protein Purification System (PPPS).

Back to news